Original Title: Optimal Strategy for Provisional Side Branch Intervention in Coronary Bifurcation Lesions. 3 – Year Outcomes of the SMART – STRATEGY Randomized Trial. Reference: Song YB et al. J Am Coll Cardiol Intv 2016;9:517-26. Courtesy of Dr. José A. G. Álvarez. The present publication is about the three year follow up outcomes of<a href="https://solaci.org/en/2016/05/09/optimal-strategy-for-side-branch-intervention-in-bifurcations/" title="Read more" >...</a>
Original Title: Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. PARTNER 2A. Reference: Martin B. Leon et al. NEJM April 2, 2016 Courtesy of Dr. Juan A. Terré Studies have shown mortality rates after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in high risk patients are similar (PARTNER 2 – Cohort B). This is<a href="https://solaci.org/en/2016/04/15/tavr-with-sapien-xt-similar-to-surgical-replacement-in-intermediate-risk-patients/" title="Read more" >...</a>
Original Title: Optimal Strategy for Provisional Side Branch Intervention in Coronary Bifurcation Lesions3-Year Outcomes of the SMART-STRATEGY Randomized Trial. Reference: Young Bin Song et al. J Am CollCardiolIntv. 2016;9(6):517-526. This study compared the long term outcomes of the conservative strategy vs. the aggressive strategy for provisional side branch intervention in coronary bifurcations. It has already<a href="https://solaci.org/en/2016/03/27/in-bifurcations-less-is-more-also-at-long-term/" title="Read more" >...</a>
Original Title: Outcomes in Patients with Transcatheter Aortic Valve Replacement and Left Main Stenting. The TAVR-LM Registry. Reference: TarunChakravarty et al. Journal of the American College of Cardiology, Vol 67, N° 8, 2016. Courtesy of Dr. Santiago F. Coroleu. High surgical risk patients with severe aortic stenosis and significant left main aortic arterydiseaseare often treated combining<a href="https://solaci.org/en/2016/03/22/tavr-lm-registry-transcatheter-aortic-valve-replacement-and-left-main-stenting/" title="Read more" >...</a>
Original Title: Left main stenting in Comparison with Surgical Revascularization 10-year outcomes of the (Left Main Coronary Stenting) LE MANS trial. Reference: Buszman P et al. J Am CollCardiolIntv. 2016;9(4):318-327. doi:10.1016/j.jcin.2015.10.044. Courtesy of Dr. Guillermo Migliaro. Long term outcomes of left main stenting are unknown. This study reports 10 year follow up outcomes of the LEMANS trial patients. The<a href="https://solaci.org/en/2016/02/29/lemans-trial-left-main-stenting-vs-surgery-at-10-years/" title="Read more" >...</a>
Original Title: Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery disease complexity. Reference: Koskinas KC et al. Circ Cardiovasc Intv. 2016; Epub ahead of print Diabetic patients ongoing PCI with drug eluting stents (DES) are at higher risk of repeat revascularization than non-diabetic patients. According to this<a href="https://solaci.org/en/2016/02/22/diabetes-has-higher-impact-on-des-outcomes-than-disease-complexity/" title="Read more" >...</a>
Original Title: Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-St segment elevation myocardial infarction: the British Heart Foundation FAMOUS–NSTEMI randomized trial. Reference: Jamie Layland et al. European Heart Journal (2015) 36, 100–111 Courtesy of Dr. José Amadeo Guillermo Álvarez. Several studies have established the value of fractional flow reserve (FFR) in<a href="https://solaci.org/en/2016/02/19/ffr-in-non-st-elevation-myocardial-infarction/" title="Read more" >...</a>
Original Title: One-year Clinical and Computed Tomography Angiographic Outcomes after Bioresorbable Vascular Scaffold Implantation during Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction. The Prague-19 Study. Reference: Widimsky P et al. Circ Cardiovasc Interv. 2015 Dec;8(12). Courtesy of Dr. Carlos Fava. Primary PCI is the most common course of treatment for ST elevation myocardial infarction (STEMI)<a href="https://solaci.org/en/2016/02/15/primary-pci-with-bioresorbable-vascular-scaffolds/" title="Read more" >...</a>
Original Title: Drug-eluting balloon versus second-generation drug-eluting stent for the treatment of restenotic lesions involving coronary bifurcations. Reference: Toru Naganuma et al. EuroIntervention 2016;11:989-995 Courtesy of del Dr. Santiago F. Coroleu. PCI involving in-stent restenosis (ISR), especially in coronary bifurcations, is associated with high rates of recurrent restenosis and the need for new revascularization. Although drug<a href="https://solaci.org/en/2016/02/10/drug-eluting-balloon-vs-second-generation-des-for-restenotic-lesions-in-bifurcations/" title="Read more" >...</a>
The Internal Mammary Artery (IMA) is the preferred conduit for bypassing the left anterior descending artery (LAD) in patients undergoing coronary artery bypass grafting. There is no systematic evaluation of the frequency and predictors of IMA failure or long-term outcomes. The PREVENT IV included 1539 patients receiving IMA-LAD revascularization with 12 and 18 month<a href="https://solaci.org/en/2015/12/24/predictors-of-internal-mammary-artery-graft-failure/" title="Read more" >...</a>